|
NEW YORK, April 10-- U.S.-China partnership in the biotech sector is promising and will benefit both patients and investors in the two countries, said U.S. biotech firms and investors. "There are many very smart scientists (in China), and they are very entrepreneurial ... We think China is a big opportunity for our (biotech drug) products," RJ Tesi, chief executive officer and chief medical officer of San Diego-based immunology company INmune Bio, told Xinhua in an interview on Tuesday after ringing the Nasdaq Stock Market closing bell here. INmune Bio recognized very early that there were investors and capital in China, and it wanted to diversify its capital base beyond North America, so it selected Univest Securities, a U.S.-based financial service provider founded primarily by Chinese-Americans, as the lead underwriter, in a bid to help it connect with Chinese investors and Chinese market, explained Tesi. He noted that "it's a strategy that has paid off well." "We think it's a good investment opportunity to act as lead placement agent of INmune Bio, so we decided to help them get listed in Nasdaq and conduct the initial public offering," said Guo Yi, chief operation officer of Univest Securities, citing the "high quality of INmune Bio's immunotherapies." Univest Securities took INmune Bio to 13 Chinese cities, including Beijing, Shanghai, Shenzhen, and Hong Kong, for road-show, helped it arrange business meetings with Chinese capital investment companies, and discussed collaborative opportunities with China's State Food and Drug Administration (SFDA), according to Guo. | 
